

HYPOTHYROIDISM

EDITORIAL Levothyroxine therapy alone restores normal serum FT₃ levels after total thyroidectomy

A small but significant proportion of patients placed on levothyroxine (L-T₄) following thyroidectomy report not achieving their preoperative sense of well-being in spite of achievement of euthyroid reference range thyrotropin (TSH) values. While 80% of circulating serum triiodothyronine (T₃) is derived from the peripheral monodeiodination of L-T₄, thyroidectomy theoretically deprives the individual of the 20% contribution of direct T₃ secretion from the thyroid. That the nonspecific symptoms might be due to consequent relative T₃ insufficiency led to over a dozen studies in the past decade examining whether T₄/T₃ combination therapy would result in an improved sense of well-being and cognitive function as compared with therapy with L-T₄ alone. Essentially all studies but one (1) found no significant difference in outcomes irrespective of the form of thyroid hormone replacement (2).

One key consideration in assessing outcomes is whether comparable levels of serum T₃ are achieved with L-T₄ therapy alone versus T₄/T₃ combination therapy. When serum T₃ levels were compared in all of the studies published to date, the comparison was done in patients with hypothyroidism who were already taking L-T₄ who were either continued on L-T₄ therapy or switched to T₄/T₃ combination therapy. Although the observations were paired, with the patients serving as their own controls, the comparison was of T₃ levels while taking L-T₄ alone as compared with taking L-T₄/T₃. Thus, there were no data on true baseline or preoperative serum T₃ levels—that is, either prior to development of hypothyroidism or prior to thyroidectomy. The rather simple study by Jonklaas et al. (3) fairly definitively addresses the issue of whether we can achieve levels of serum T₃ with L-T₄ replacement alone that are just as “normal” as a given patient’s preoperative serum T₃ levels. If the basis for reports of mood or motor dysfunction were due to T₃ insufficiency, patients achieving postoperative T₃ levels comparable to their baseline preoperative T₃ levels should feel no different once recovered from any perioperative symptoms unrelated to thyroid hormone replacement. In the study by Jonklaas et al., reference-range TSH levels were achieved in 94% of patients by the end of the study, although many patients had higher TSH levels shortly after surgery that required titration with an increased dosage of L-T₄.

Because T₄ is converted to T₃, it would follow that ultimately near-normal concentrations of serum T₃ could be restored by administering T₄ alone, providing enough L-T₄ is given. As had been seen in earlier published studies, attainment of T₃ levels in the normal range requires a dosage of L-

T₄ that is associated with free thyroxine (FT₄) levels on replacement that are higher than preoperative basal FT₄ values. Nevertheless, the study provides proof of principle that sufficient levels of serum T₃, statistically no different from patients’ preoperative basal T₃ levels, can be achieved during treatment with L-T₄ alone, and are associated as well with comparably normal TSH levels. Unfortunately, Jonklaas et al. did not assess patient satisfaction, mood, cognition, or responses to symptom questionnaires. It would have been of interest to determine whether restoration of serum T₃ levels to their original values was associated with a universal sense of well-being in all subjects or whether there was a subgroup who failed to achieve their baseline sense of well-being in spite of having comparable serum T₃ levels.

While there may be other, yet poorly understood, reasons why some patients continue to report reduced mood, memory, and psychomotor function while on replacement therapy with L-T₄ alone, this study confirms that such symptoms are not due to T₃ insufficiency, given an adequate L-T₄ dosage and normalization of TSH. In view of the controversy over what constitutes a “normal” TSH level (4) and because achievement of a TSH level within the population reference range may not be equivalent to achieving a patient’s individual “normal” range (5), perhaps we should be titrating L-T₄ dosages to achieve both the latter “personal best” TSH level and the preoperative or presurgical T₃ levels when known. Is it possible that the fraction of patients who report symptoms are those whom we have failed to truly restore to euthyroidism? Indeed, several studies have shown that 15 to 27% of patients treated by endocrinologists are undertreated (6,7). Moreover, these figures are based on TSH values at an upper limit of the reference range of 4.5 to 5.3 mIU/L, and the percentages of undertreated patients would be considerably higher given an upper limit of normal for TSH of 3 to 3.5 mIU/L. Conceivably, the number of patients with these persistent symptoms would be much reduced if patients were treated with sufficient L-T₄ to bring TSH levels to the range of 1.0 to 1.5 mIU/L.


Leonard Wartofsky, MD
Washington Hospital Center
Washington, DC

References

1. Bunevicius R, Kazanavicius G, Zalinkevicius R, Prange AJ Jr. Effects of thyroxine as compared with thyroxine plus triiodothyronine in patients with hypothyroidism. *N Engl J Med* 1999;340:424-9.
2. Wartofsky L. Combined levotriiodothyronine and levothyroxine therapy for hypothyroidism: are we a step closer to the magic formula? *Thyroid* 2004;14:247-8.
3. Jonklaas J, Davidson B, Bhagat S et al. Triiodothyronine levels in athyreotic individuals during levothyroxine therapy. *JAMA* 2008;299:769-777.
4. Wartofsky L, Dickey R. The evidence for a narrower thyrotropin reference range is compelling. *J Clin Endocrinol Metab* 2005;90: 5483-8.
5. Andersen S, Pedersen KM, Bruun NH, Laurberg P. Narrow individual variations in serum T(4) and T(3) in normal subjects: a clue to the understanding of subclinical thyroid disease. *J Clin Endocrinol Metab* 2002;87:1068-72.
6. Canaris GJ, Manowitz NR, Mayor G, Ridgway EC. The Colorado thyroid disease prevalence study. *Arch Intern Med* 2000;160:526-34.
7. Ross DS, Daniels GH, Gouveia D. The use and limitations of a chemiluminescent thyrotropin assay as a single thyroid function test in an out-patient endocrine clinic. *J Clin Endocrinol Metab* 1990;71:764-9.

Citation

Wartofsky L. Levothyroxine therapy alone restores normal serum FT3 levels after total thyroidectomy. *Clinical Thyroidology* [serial online]. 2008;20(3):6-7. Available at: http://thyroid.org/professionals/publications/clinthy/volume20/issue3/clinthy_v203_6_7.pdf Accessed Month Day, Year.



[Online Registration Now Open>>](#)